Why is it there's a tremendous amount of eye-rolling in this thread every time a study is released that shows HCQ might be effective for treating COVID-19 but when an equally-shaky study comes forward showing negative results, this forum accepts the study as additional proof that HCQ is not a good solution and nobody says "bad science"?
The study in question involved HCQ administered in a hospital setting, which suggests that HCQ and HCQ+AZ given to seriously ill patients may not have good outcomes. We already have a good idea that this is the wrong time in the disease progression to administer HCQ. The positive results of past small studies suggests that HCQ + AZ when given early in an outpatient setting, such as the results that Dr. Zelenko of New York has been claiming or given in the French studies by Dr. Raoult and others, can be quite positive. What this newest study did provide us with is an additional suggestion that HCQ is not the antiviral of choice for seriously-ill patients of COVID-19 in a hospital setting. Preliminary and leaked data regarding remdesivir suggests it is a much better antiviral for being administered in a hospital setting.
Bottom line: this short study which apparently did not involve random selection of patients is of questionable value due to its methodologies, but it does suggest that in a hospital setting with seriously ill COVID-19 patients HCQ is not the antiviral of choice. That doctors are giving this medication in that setting instead of remdesivir is depressing, given preliminary indications of both drugs. The study also highlights the need to differentiate when in the disease progression HCQ is given, if we wish to derive useful information from the study. Specifically, what are the results in a controlled study when HCQ+AZ are given on an outpatient basis early in the disease's progression?